Dr. Nedal Safwat Is Named Chief Strategy Officer of Accelerate Diagnostics

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Dr. Nedal Safwat has been named chief strategy officer of Accelerate Diagnostics.

Dr. Nedal Safwat joins Accelerate from BioMerieux, the world’s leading microbiology diagnostics company.

Jack Phillips, President and Chief Executive Officer of Accelerate Diagnostics, commented, “We are excited to add a leader to our team with such extensive commercial and operational experience in the microbiology diagnostics space.  In this newly created position as Chief Strategy Officer, Nedal will take a leadership role in the implementation of our recently launched new product strategy and will be responsible for driving the expansion of this strategy over the long term.  I am confident that his experience in the microbiology industry and commitment to growth make him a great fit for our team as we continue to execute against our long-term vision for Accelerate Diagnostics.”

“I am thrilled to join Accelerate Diagnostics, as the company plays a critical role in delivering high medical value tests that are transforming the standard of care.  In my new role, I look forward to working with the Accelerate team to continue delivering products that drive better clinical outcomes for patients, reinforce antibiotic stewardship, and lower the overall cost of the treatment of serious infections,” said Dr. Safwat.

Dr. Nedal Safwat brings significant experience in the microbiology diagnostics and life sciences industries.  During his 11 years at BioMerieux, he held a variety of roles of increasing importance, including positions in sales, product management, global marketing, and, most recently, leading the ID/AST Franchise. Prior to joining BioMerieux, Dr. Safwat held positions at Luminex Corporation, Strategic Diagnostics Incorporated, Miltenyi Biotec Incorporated, and Bayer Diagnostics.

Dr. Safwat received his bachelor’s and doctorate degrees in biochemistry from North Carolina State University.  He is also an alumni of CEDEP (The European Centre for Executive Development).

spot_img

DON'T MISS

Related Articles